For example, we found that the IC50 values of several anti-cancer drugs decreased in the high- HOXA3 group, including abiraterone, Trametinib, VAF-347, BRD-K09344309, BRD-K34099515 and erlotinib (Supplementary Figure 10), indicating that patients exhibiting high HOXA3 expression levels are relatively sensitive to these anti-cancer drugs. This evidence concerns the gene HOXA3 and cancer.